First-line therapy for advanced colorectal cancer

Current Oncology Reports

Volumn 7, Issue 3, 2005, Pages 167-172

  de Gramont, Aimery ^a   Tournigand, Christophe ^a   Louvet, Christophe ^a   Maindrault Goebel, Frédérique ^a   André, Thierry ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PEMETREXED; VASCULOTROPIN INHIBITOR;

ACNE; ADVANCED CANCER; ALOPECIA; ARTERY THROMBOSIS; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG TARGETING; DRUG TOLERABILITY; ECONOMIC ASPECT; FEBRILE NEUTROPENIA; HUMAN; INTESTINE PERFORATION; MEDICAL DECISION MAKING; METASTASIS; MODULATION; MONOTHERAPY; NAUSEA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PROGNOSIS; SALVAGE THERAPY; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT PLANNING; VOMITING;

EID: 18744364225     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-005-0069-y     Document Type: Article

References (31)

1. de Gramont A, Bosset JF, Milan C, et al.: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997, 15:808-815.
2. Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998, 16:301-308.
3. Hoff PM, Ansari F, Batist G, et al.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001, 19:2282-2292.
4. Van Cutsem E, Twelves C, Cassidy J, et al.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001, 19:4097-4106.
5. Rougier P, Van Cutsem E, Baietta E, et al.: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352:1407-1412.
6. Cunningham D, Glimelius B: A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol 1999, 26:6-12.
7. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343:905-914.
8. Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047.
9. de Gramont A, Vignoud J, Tournigand C, et al.: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997, 33:214-219.
10. Maindrault-Goebel F, de Gramont A, Louvet C, et al.: High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 2001, 37:1000-1005.
11. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
12. Goldberg RM, Sargent DJ, Morton RF, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22:23-30.
13. Goldberg R, Sargent D, Morton RF, et al.: N9741: FOLFOX (oxaliplatin(Oxal) 5-fluorouracil (5-FU)/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): final efficacy data from an intergroup study [abstract]. Proc ASCO 2004, 23:275.
14. Tournigand C, Andre T, Achille E, et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22:229-237.
15. Köhne C, Van Cutsem E, Wils J, et al.: Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer. Results of the EORTC GI Group Study 40986 [abstract]. Proc ASCO 2003, 22:254.
16. Grothey A, Deschler B, Kroening H, et al.: phase III study of bolus 5-fluorouracil (5FU)/ folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/ FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC) [abstract]. Proc ASCO 2002, 21:129a.
17. Grothey A, Jordan K, Keliner O, et al.: Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC) [abstract]. Proc ASCO 2003, 22:255.
18. Giacchetti S, Bjarnason G, Garufi C, et al.: First line infusion of 5-fluorouracil, leucovorin and oxaliplatin for metastatic colorectal cancer: 4-day chronomodulated (FFL4-10) versus 2-day FOLFOX2: a multicenter randomized phase III trial of the chronotherapy group of the European Organization for Research and Treatment of Cancer (EORTC 05963) [abstract]. Proc ASCO 2004, 23:252.
19. Andre T, Louvet C, Maindrault-Goebel F, et al.: CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999, 35:1343-1347.
20. Mitry E, Tournigand C, André T, et al.: Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer: a pooled analysis of 254 patients included in 2 randomised trials [abstract]. Proc ASCO 2004, 23:264.
21. Mabro M, Louvet C, Andre T, et al.: Bimonthly leucovorin, infilsion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. Am J Clin Oncol 2003, 26:254-258.
22. Mabro M, Artru P, Flesh M, et al.: Irinotecan, 5-fluorouracil infusion and leucovorin (FOLFIRI-3) in pretreated patients with metastatic colorectal cancer: Results of a multicenter phase II study [abstract]. Proc ASCO 2003, 22:280.
23. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
24. Tabernero J, Van Cutsem E, Sastre J: An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR): preliminary results [abstract]. Proc ASCO 2004, 23:248.
25. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
26. Kabbinavar F, Schultz J, McCleod M, et al.: Bevadzumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal (CRC) in subjects who are not suitable candidates for first-line CPT-11 [abstract]. Proc ASCO 2004, 23:249.
27. Kohne C-H, Cunningham D, Di Costanzo F, et al.: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002, 13:308-317.
28. Souglakos J, Ziras N, Polyzos A, et al.: Oxaliplatin (L-OHP) combined with irinotecan (CPF-11), leucovorin (LV) and fluorouracil (5-FU) compared with irinotecan, leucovorin and fluorouracil as first-line treatment for metastatic colorectal cancer (MRC): preliminary results of a multicenter randomized phase III trial [abstract]. Proc ASCO 2004, 23:253.
29. Grothey A, Sargent D, Goldberg RM, et al.: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004, 22:1209-1214.
30. de Gramont A, Cervantes A, André T, et al.: OPTIMOX study: FOLFOX7/LV5FU2 compared to FOLFOX4 in patients with advanced colorectal cancer [abstract]. Proc ASCO 2004, 23:251.
31. Maughan TS, James RD, Kerr DJ, et al.: Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 2003, 361:457-464.